RVNC Revance Therapeutics Inc

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14D-9

(Rule 14d-101)

Solicitation/Recommendation Statement

Under Section 14(d)(4) of the Securities Exchange Act of 1934

Revance Therapeutics, Inc.

(Name of Subject Company)

Revance Therapeutics, Inc.

(Name of Persons Filing Statement)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

761330109

(CUSIP Number of Class of Securities)

Mark J. Foley

President and Chief Executive Officer

1222 Demonbreun Street, Suite 2000

Nashville, TN 37203

(651) 724-7755

(Name, address, and telephone numbers of person authorized to receive notices and communications

on behalf of the persons filing statement)

With copies to:

Howard Ellin

Demetrius Warrick

Skadden, Arps, Slate, Meagher & Flom LLP

One Manhattan West

New York, New York 10001

(212) 735-3000

This Schedule 14D-9 filing relates solely to preliminary communications made before the commencement of a planned tender offer (the “Offer”) by Reba Merger Sub, Inc. (“Merger Sub”), a wholly owned subsidiary of Crown Laboratories, Inc. (“Parent” and together with Merger Sub, the “Buyer Parties”), for all of the outstanding shares of common stock, par value $0.001 per share of Revance Therapeutics, Inc. (the “Company”), to be commenced pursuant to the Agreement and Plan of Merger, dated August 11, 2024 (the “Merger Agreement”), among the Company, Merger Sub and Parent. If successful, the Offer will be followed by a merger of Merger Sub with and into the Company (the “Merger”).

This Schedule 14D-9 filing consists of the following documents relating to the proposed Offer and Merger:

Additional Information and Where to Find It

The tender offer described in this Schedule 14D-9 has not yet commenced. This Schedule 14D-9 is not an offer to buy nor a solicitation of an offer to sell any securities of the Company. The solicitation and the offer to buy shares of the Company’s common stock will be made only pursuant to a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and other related materials that the Buyer Parties intend to file with the SEC. In addition, the Company will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. Once filed, such documents will be mailed to the stockholders of the Company free of charge and investors will also be able to obtain a free copy of these materials (including the tender offer statement, Offer and the related letter of transmittal) as well as the Solicitation/Recommendation Statement and other documents filed by the Buyer Parties and the Company with the SEC at the website maintained by the SEC at www.sec.gov. Investors may also obtain, at no charge, any such documents filed with or furnished to the SEC by the Company under the “News” section of the Company’s website at www.revance.com. The information contained in, or that can be accessed through, the Company’s or Parent’s website is not a part of, or incorporated by reference herein.

INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THESE DOCUMENTS WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME), INCLUDING THE TENDER OFFER MATERIALS (INCLUDING THE OFFER, THE RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT OF THE COMPANY AND ANY AMENDMENTS THERETO, AS WELL AS ANY OTHER DOCUMENTS RELATING TO THE TENDER OFFER AND THE MERGER THAT ARE FILED WITH THE SEC, CAREFULLY AND IN THEIR ENTIRETY PRIOR TO MAKING ANY DECISIONS WITH RESPECT TO WHETHER TO TENDER THEIR SHARES INTO THE TENDER OFFER BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER.

Cautionary Statement on Forward-Looking Statements

Certain statements either contained in or incorporated by reference into this document are “forward-looking statements.” The use of words such as “anticipates,” “hopes,” “may,” “should,” “intends,” “projects,” “estimates,” “expects,” “plans” and “believes,” among others, generally identify forward-looking statements. All statements, other than statements of historical fact, are forward-looking statements. These forward-looking statements include, among others, statements relating to the Company’s and Parent’s future financial performance, business prospects and strategy, expectations with respect to the Offer and the Merger, including the timing thereof and our and the Buyer Parties’ ability to successfully complete such transactions and realize the anticipated benefits. Actual results could differ materially from those contained in these forward-looking statements for a variety of reasons, including, among others, the risks and uncertainties inherent in the Offer and the Merger, including, among other things, regarding how many of the Company stockholders will

tender their shares in the Offer, the possibility that competing offers will be made, the ability to obtain requisite regulatory approvals, the ability to satisfy the conditions to the closing of the Offer and the Merger, the expected timing of the Offer and the Merger, the possibility that the Merger will not be completed, difficulties or unanticipated expenses in connection with integrating the parties’ operations, products and employees and the possibility that anticipated synergies and other anticipated benefits of the transaction will not be realized in the amounts expected, within the expected timeframe or at all, the effect of the announcement of the Offer and the Merger on the Company’s and Parent’s business relationships (including, without limitations, partners and customers), the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement, the expected tax treatment of the transaction, and the impact of the transaction on the businesses of the Company and Parent, and other circumstances beyond the Company’s and Parent’s control. You should not place undue reliance on these forward looking statements. Certain of these and other risks and uncertainties are discussed in Company’s and Parent’s filings with the SEC, including the Schedule TO (including the offer to purchase, letter of transmittal and related documents) the Parent and Merger Sub will file with the SEC, and the Solicitation/Recommendation Statement on Schedule 14D-9 the Company will file with the SEC, and our most recent Form 10-K and Form 10-Q filings with the SEC. Except as required by law, neither we nor the Buyer Parties undertake any duty to update forward-looking statements to reflect events after the date of this document.

Exhibit 99.1

Crown Laboratories and Revance Announce Entry Into Merger Agreement

Combination provides opportunity to create a leading, innovative, high-growth aesthetics and skincare company

Brings together two high-quality, complementary product lines

Combined company’s flagship brands to include DAXXIFY^® (toxin), the RHA^® Collection (filler), SkinPen^® (microneedling), PanOxyl^® (acne), Blue Lizard^® (sunscreen), and StriVectin^® (anti-aging)

Opportunity for global commercialization capabilities with coverage of >10,000 medical professionals, mass retailers, specialty retailers, club retailers, and an ecommerce channel

New product flow potential through internal product development and an integrated manufacturing operation

Experienced leadership team that leverages the strength of both organizations

Johnson City and Nashville, Tenn. – August 12, 2024 — Crown Laboratories, Inc. (“Crown”), a privately held, global innovative leader in the skincare industry, and Revance Therapeutics, Inc. (“Revance”) (NASDAQ: RVNC), a biotechnology company aimed at setting the new standard in healthcare with innovative aesthetic and therapeutic offerings, today announced that they have entered into a merger agreement pursuant to which the companies seek to merge the two complementary organizations.

Under the terms of the agreement, which has been unanimously approved by Revance’s Board of Directors, Crown will commence a tender offer to acquire all outstanding shares of Revance’s common stock for $6.66 per share in cash, representing a total enterprise value of $924 million. The purchase price represents a premium of 89% over Revance’s closing market price on August 9, 2024, and a 111% premium to Revance’s 60-day volume-weighted average price.

“This is a significant step forward in Crown’s vision to become a fully integrated global aesthetics and skincare company, bringing innovative solutions to physicians, patients and consumers in the incredibly dynamic aesthetics and skincare market,” said Jeff Bedard, founder and Chief Executive Officer of Crown. “Revance has an impressive track record in developing innovative aesthetics offerings that will complement Crown’s innovative line of skincare products. As a combined company, we have the opportunity to create a comprehensive portfolio of high-growth products for all stages of life, and we will be committed to investing in education, training, and practice support for aesthetics providers across the United States.”

Upon completion of the transaction, Crown Laboratories expects to be one of the leading global aesthetics and skincare companies in an attractive, high-growth market, with an industry-leading portfolio of 10+ cutting-edge skin health and aesthetic brands, and one of the largest distribution footprints in skincare across medical, retail and e-commerce channels.

Mark J. Foley, President and Chief Executive Officer of Revance said, “Over the past several years, Revance has brought to the market innovative aesthetic and therapeutic offerings that have elevated patient and physician experiences. We are excited about this transaction and to be joining forces with Crown Laboratories, which will enable us to broaden our provider network as well as provide us with an expanded portfolio of products. We also believe that the merger provides substantial value for our stockholders. Crown shares our commitment to innovation and scale and will help us accelerate our growth. Scale and product breadth are important factors in the markets in which we compete and, by combining with Crown, we will be able to offer our customers a more compelling range of products and services while, at the same time, benefiting from the combined strength of our collective commercial organizations.”

Transaction Details

The transaction is expected to close by year end. Following completion of the merger, Revance will be wholly owned by Crown and Revance’s stock will no longer be publicly traded on Nasdaq.

The transaction is subject to stockholders validly tendering shares representing at least a majority of the voting power of Revance, required regulatory approvals and other customary closing conditions.

Following the successful closing of the tender offer, Crown will acquire any shares of Revance that are not tendered in the tender offer through a second-step merger for the same consideration as paid in the tender offer.

Revance’s Board of Directors unanimously recommends that Revance’s stockholders tender their shares in the tender offer.

Further information regarding the terms and conditions in the definitive transaction agreement will be provided in the tender offer materials on Schedule TO and Schedule 14D-9, which will be filed with the U.S. Securities and Exchange Commission in connection with the transaction.

Advisors

Centerview Partners LLC is serving as exclusive financial advisor for Revance; Skadden, Arps, Slate, Meagher & Flom LLP is serving as legal advisor for Revance.

PJT Partners is serving as financial advisor to Crown; Kirkland & Ellis LLP and Lowenstein Sandler LLP are serving as legal advisors to Crown.

About Crown Laboratories

Crown, a privately held, fully integrated global skincare company, is committed to developing and providing a diverse portfolio of aesthetic, premium and therapeutic skincare products that improve the quality of life for its consumers throughout their skincare journey. An innovative company focused on skin science for life, Crown’s unyielding pursuit of delivering therapeutic excellence and enhanced patient outcomes is why it has become a leader in Dermatology and Aesthetics. Crown has been listed on the Inc.

5000 Fastest Growing Privately Held Companies List for 11 years and has expanded its distribution to over 50 countries. For more information, visit www.crownlaboratories.com.

The “Crown” logo, PanOxyl and Blue Lizard are registered trademarks of Crown Laboratories, Inc. SkinPen and StriVectin are registered trademarks of Bellus Medical, LLC and StriVectin Operating Company, Inc., respectively.

About Revance

Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers. RHA^® technology is proprietary to and manufactured in Switzerland by Teoxane SA. Revance has partnered with Teoxane, SA to supply HA fillers for U.S. distribution. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China. Revance’s global headquarters and experience center is located in Nashville, Tennessee. Learn more at Revance.com, RevanceAesthetics.com, DAXXIFY.com, HCP.DAXXIFYCervicalDystonia.com, or connect with us on LinkedIn.

“Revance”, the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc.

Resilient Hyaluronic Acid^® and RHA are trademarks of TEOXANE SA.

# # #

Contacts

Media:

Alecia Pulman

ICR

Crown@icrinc.com

Investors:

Laurence Watts

NewStreet

laurence@newstreetir.com

Additional Information and Where to Find It

The tender offer described above has not yet commenced. This communication is not an offer to buy nor a solicitation of an offer to sell any securities of Revance Therapeutics, Inc. The solicitation and the offer to buy shares of Revance’s common stock will only be made pursuant to a tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and other related materials that Crown Laboratories and its acquisition subsidiary intends to file with the Securities and Exchange Commission (SEC). In addition, Revance will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. Once filed, such documents will be mailed to the stockholders of Revance free of charge and investors will also be able to obtain a free copy of these materials (including the tender offer statement, Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement) and other documents filed by Crown Laboratories and Revance with the SEC at the website maintained by the SEC at www.sec.gov. Investors may also obtain, at no charge, any such documents filed with or furnished to the SEC by Revance under the “News” section of Revance’s website at www.revance.com. The information contained in, or that can be accessed through, Revance’s or Crown’s website is not a part of, or incorporated by reference herein.

INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THESE DOCUMENTS WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME), INCLUDING TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT OF REVANCE AND ANY AMENDMENTS THERETO, AS WELL AS ANY OTHER DOCUMENTS RELATING TO THE TENDER OFFER AND THE MERGER THAT ARE FILED WITH THE SEC, CAREFULLY AND IN THEIR ENTIRETY PRIOR TO MAKING ANY DECISIONS WITH RESPECT TO WHETHER TO TENDER THEIR SHARES INTO THE TENDER OFFER BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER.

Forward-Looking Statements

Certain statements contained in this press release are “forward-looking statements.” The use of words such as “anticipates,” “hopes,” “may,” “should,” “intends,” “projects,” “estimates,” “expects,” “plans” and “believes,” among others, generally identify forward-looking statements. All statements, other than statements of historical fact, are forward-looking statements. These forward-looking statements include, among others, statements relating to Revance’s and Crown’s future financial performance, business prospects and strategy, expectations with respect to the tender offer and the Merger, including the timing thereof and Revance’s and Crown’s ability to successfully complete such transactions and realize the anticipated benefits. Actual results could differ materially from those contained in these forward-looking statements for a variety of reasons, including, among others, the risks and uncertainties inherent in the tender offer and the Merger, including, among other things, regarding how many of Revance stockholders will tender their shares in the tender offer, the possibility that competing offers will be made, the ability to obtain requisite regulatory approvals, the ability to satisfy the conditions to the closing of the tender offer and the Merger, the expected timing of the tender offer and the Merger, the possibility that the Merger will not be completed, difficulties or unanticipated expenses in connection with integrating the parties’ operations, products and employees and the possibility that anticipated synergies and other anticipated benefits of the transaction will not be realized in the amounts expected, within the expected timeframe or at all, the effect of the announcement of the tender offer and the Merger on Revance’s and Crown’s business relationships (including, without limitations, partners and customers), the occurrence of any event, change or other circumstances that could give rise to the termination of the Merger Agreement, the expected tax treatment of the transaction, and the impact of the transaction on the businesses of Revance and Crown, and other circumstances beyond Revance’s and Crown’s control. You should not place undue reliance on these forward looking statements. Certain of these and other risks and uncertainties are discussed in Revance’s and Crown’s filings with the SEC, including the Schedule TO (including the offer to purchase, letter of transmittal and related documents) Crown and its acquisition subsidiary will file with the SEC, and the Solicitation/Recommendation Statement on Schedule 14D-9 the Company will file with the SEC, and Revance’s most recent Form 10-K and Form 10-Q filings with the SEC. Except as required by law, neither Revance nor Crown undertakes any duty to update forward-looking statements to reflect events after the date of this press release.

Exhibit 99.2

All Employee CEO Memo

I am writing to share an important milestone and some very exciting news about our company, as we have taken a significant step forward in the future growth and development of Revance.

Today we announced that Revance has agreed to merge with Crown Laboratories, a global innovative leader in the skincare industry. For background, Crown was started in 2000 by Jeff Bedard, Founder & CEO, with a mission to be a fully integrated skincare company with a diverse portfolio of aesthetic and therapeutic products. You may recognize many of their brands, including SkinPen^®, BIOJUVE^®, ProGen PRP^® Eclipse, Votesse^®, MicroPen EVO , as well as skincare brands including Panoxyl, StriVectin, and Blue Lizard.

Upon completion of this merger, we believe the combined company will be one of the leading global aesthetics and skincare companies, encompassing one of the most comprehensive portfolios of cutting-edge brands, and well positioned in an attractive, high-growth sector. Until we close the deal, which we expect to do by year end, we will remain a publicly-traded company.

This decision is anchored in our commitment and pursuit to continue growing our brands globally to best serve our partners, consumers, customers and employees. Our Board of Directors and advisors thoroughly evaluated the transaction with Crown and are confident that this agreement will provide a promising opportunity to realize significant value for our key stakeholders, including our valued employees and customers.

Importantly, Crown shares our mission-driven culture, ability to act quickly and passion to think big. They are aligned with our focus on creating skincare, aesthetic and therapeutic offerings that enhance patient outcomes and physician experience, and like us, thrive on collaborating with some of the best minds working towards driving innovation.

On a tactical note, both Revance and Crown will continue to operate as separate and independent companies, and it will be business as usual at both companies until closing. This means it is critical that we remain focused on our day-to-day responsibilities and delivering on our key objectives. I will host an All Hands meeting this afternoon at 3:00pm CST to share more details and to answer questions – an invite will be forthcoming. To submit your question please click here* by 12:00 PM CT. Additionally, we will hold our regularly scheduled All Hands meeting this Wednesday, August 14th welcoming Crown leadership, to share their vision for the future. Recognizing there may be questions that we cannot answer right away, we will do our best to share what we can today and will keep you updated as more information becomes available.

As we go through this process, outside parties may inquire about the transaction. We ask that you do not comment on the transaction or provide any details. If anyone reaches out to you with questions, please refer them Revance@FGSGlobal.com.

Finally, I want to thank you all for your continued dedication to the work you do every day on behalf of our partners and patients. You are truly an incredible team, and it is because of your continued dedication to our company and partners that we are able to continue delivering excellence and take this step forward towards future growth.

Best,

Mark

* In the version of this communication that was sent to the Company’s employees, a hyperlink to an internal Company site was embedded in this sentence for the purpose of allowing employees to submit questions.

Exhibit 99.3

Employee FAQs

These are designed to support senior leaders when prompted by employees with questions regarding the deal announcement

Q. Who is Crown Laboratories?

A. Crown Laboratories, Inc. (“Crown”), is a privately held, global innovative leader in the skincare industry dedicated to developing and providing a diverse portfolio of safe and effective scientific solutions for life-long healthy skin. Included in Crown’s portfolio are aesthetics, skincare and therapeutic offerings (SkinPen^®, BIOJUVE^®, StiVectin^®, PanOxyl^®, Blue Lizard^® sunscreen, and more)

Q. Why was this deal done?

A. This decision is anchored in our commitment and pursuit to continue growing our brands globally to best serve our partners, consumers, customers and employees. The announced deal will provide a long runway of growth and opportunities to be one of the industry leaders in an attractive, high-growth sector.

Q. Will we be keeping our company name or will there be a new name?

A. We don’t have an answer to that today, however we anticipate clarity on that in the coming weeks.

Q, Will we continue to be a public company.

A. Upon transaction close we will be wholly owned by Crown, and our stock will no longer be publicly traded on Nasdaq. The trading of the stock will cease on the date that the transaction closes.

Q. Will our Newark or Nashville site be closed?

A. Crown recognizes the immense value that both our Newark and Nashville centers of excellence bring. They are excited to welcome our teams into the Crown family and understand the specialized expertise of our Newark and Nashville employees, along with the innovation and complexity of work that occurs there. It will be business as usual at both companies until closing.

Q. Where will the company headquarters be?

A. While the location of where company headquarters will be is undecided today, Crown has communicated their intent in maintaining a strong Nashville presence.

Q. Are any of our company goals or objectives changing?

A. Our revenue, operational and therapeutics goals remain intact for 2024.

Employee FAQs

These are designed to support senior leaders when prompted by employees with questions regarding the deal announcement

Q. How will our company culture change?

A. While assimilating two company cultures will lead to change, Crown’s values of Teamwork, Character, Accountability, Excellence, Diversity and Work-Life Balance show positive synergies between our cultures.

Q. What will happen to ECOM?

A. ECOM will be partnering closely with the Crown and Revance teams to ensure a successful integration over the next couple of months. We will share information about the combined company’s executive team and go-forward planning when we are able to do so after the closing.

Q. Is my manager staying the same?

A. Prior to closing of the transaction, there will be no change to your immediate supervisor, other than what is expected in the normal course of business. While we understand reporting relationships are top-of-mind for many employees, it is premature to speculate on the specifics of the future organizational structure following the closing. We will share updates as we have more details to provide.

Q. How long will integration take and what happens during integration?

A. The transaction is expected to close by year end, subject to achieving required regulatory approvals and the satisfaction of other customary closing conditions.

Q. Will my job be eliminated?

A. Prior to closing of the transaction Revance and Crown will continue to operate as independent companies, and it will be business as usual at both companies until closing. Recognizing this change can feel unsettling, Crown does have plans for global growth and expansion and will look to this talented team to support that vision after closing.

Q. Will my title and pay remain the same?

A. As a result of this transaction, there are no plans to modify titles or salaries.

Employee FAQs

These are designed to support senior leaders when prompted by employees with questions regarding the deal announcement

Q. How will my equity be treated?

A. Vested equity will be converted into cash in your E*trade account at the closing of the deal. Unvested equity (other than Options with a strike price higher than the announced purchase price) will convert to cash and vest on the same terms as outlined in the grant agreement. For specific questions please contact stockadmin@revance.com.

Q. How will my stock options be treated?

A. Non-qualified stock options or NQSOs only have value if the strike price is lower than the announced share purchase price. NQSOs with a higher strike price than the announced purchase price do not have value and will be canceled at the close of the deal. For specific questions please contact stockadmin@revance.com.

Q. How will my benefits be changing?

A. You will continue to maintain the same medical/dental/vision/life insurance until the close of the transaction. We anticipate employees will be invited into the Crown open enrollment process in the coming weeks. There will not be a break in insurance coverage.

Q. Will I have to relocate?

A. No, there are no current plans for employees to relocate, and prior to closing of the transaction, we remain business-as-usual.

Q. Will our holiday schedule be changing?

A. All holidays for the duration of calendar year 2024 will be observed.

Q. What are my options if I don’t want to work for the new company?

A. Your employment remains at will and you can choose to voluntarily resign at any time, however we encourage you to take the time to get to know Crown before deciding to resign. Crown has shared an exciting vision of their growth trajectory and have a compelling employer value proposition.

Employee FAQs

These are designed to support senior leaders when prompted by employees with questions regarding the deal announcement

Q. Does this mean I am no longer obligated to my sign-on / relocation / retention repayment agreement once the deal closes?

A. Employees will continue to be obligated under any repayment agreements executed with Revance.

Q. What happens if I am currently on a work Visa or have a pending sponsorship?

A. All visa cases will be reviewed and individuals will contacted before the deal closes to discuss next steps.

Q. When will we receive more information about Crown and plans for the future?

A. All Hands meetings are planned for Monday, Aug 12^th and Weds, Aug 14^th to provide more information and introduce leaders from Crown. In addition, members of ECOM will be visiting the Newark site Tues, Aug 20^th to host a Townhall Meeting. Beyond that there will be periodic updates and more information provided as it becomes available.

Sales Employee FAQs

These are designed to support sales leaders when prompted by sales employees with questions regarding the deal announcement

Q. How are customers being notified about the deal?

A. Aside from the press release, our leadership team are reaching out to key customers over the next several days. Team members who manage our customer relationships will be provided with specific talking points to help with Q&A.

Q. What do I say to customers who call with concerns as a result of the deal?

A. A Customer FAQs will be provided to the sales team to help answer customer questions. For specific questions related to the deal please refer them to our public relations firm, FGS Global at Revance@FGSGlobal.com.

Q. How will the deal impact customers? What differences will they see?

A. There are no changes to our products or services prior to completion of the transaction. We are committed to staying in touch with our customers if any post deal changes are made.

Q. Will the sales reps keep their existing territories and customer bases?

A. The are no changes to territories or customers as a result of this announcement or during the transition phase, so territories and customers are considered business-as-usual.

Q. What does this deal mean for the therapeutics franchise?

A. Crown has expressed enthusiasm in bringing our companies together expanding products and services across portfolios. There will be an opportunity to hear from Crown leadership in the coming weeks about their vision for therapeutics. Until then there are no changes to our business priorities as we execute on our objectives the back half of 2024.